CL2007001692A1 - Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina. - Google Patents
Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina.Info
- Publication number
- CL2007001692A1 CL2007001692A1 CL200701692A CL2007001692A CL2007001692A1 CL 2007001692 A1 CL2007001692 A1 CL 2007001692A1 CL 200701692 A CL200701692 A CL 200701692A CL 2007001692 A CL2007001692 A CL 2007001692A CL 2007001692 A1 CL2007001692 A1 CL 2007001692A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- hydroxi
- propenamide
- indol
- responds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80452306P | 2006-06-12 | 2006-06-12 | |
US86999306P | 2006-12-14 | 2006-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007001692A1 true CL2007001692A1 (es) | 2008-05-09 |
Family
ID=38564366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200701692A CL2007001692A1 (es) | 2006-06-12 | 2007-06-11 | Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina. |
Country Status (38)
Country | Link |
---|---|
US (3) | US20090197936A1 (es) |
EP (1) | EP2032531B1 (es) |
JP (2) | JP2009540005A (es) |
KR (2) | KR101629352B1 (es) |
AR (1) | AR061298A1 (es) |
AU (1) | AU2007257962B2 (es) |
BR (1) | BRPI0712771A2 (es) |
CA (1) | CA2654439C (es) |
CL (1) | CL2007001692A1 (es) |
CR (1) | CR10439A (es) |
DK (1) | DK2032531T3 (es) |
EA (1) | EA015212B1 (es) |
EC (1) | ECSP088979A (es) |
ES (1) | ES2570934T3 (es) |
GE (1) | GEP20105125B (es) |
GT (1) | GT200800279A (es) |
HK (1) | HK1126496A1 (es) |
HN (1) | HN2008001859A (es) |
HR (1) | HRP20160291T1 (es) |
HU (1) | HUE027126T2 (es) |
IL (1) | IL195087A (es) |
JO (1) | JO3138B1 (es) |
MA (1) | MA30563B1 (es) |
ME (1) | ME00531B (es) |
MX (1) | MX2008015901A (es) |
MY (1) | MY147345A (es) |
NO (1) | NO341871B1 (es) |
NZ (1) | NZ572547A (es) |
PE (1) | PE20080937A1 (es) |
PL (1) | PL2032531T3 (es) |
RS (1) | RS54640B1 (es) |
SI (1) | SI2032531T1 (es) |
SM (1) | SMP200900002B (es) |
SV (1) | SV2008003126A (es) |
TN (1) | TNSN08501A1 (es) |
TW (1) | TWI409254B (es) |
UY (1) | UY30403A1 (es) |
WO (1) | WO2007146715A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY149337A (en) | 2006-06-12 | 2013-08-30 | Novartis Ag | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
AU2008204928B2 (en) * | 2007-01-10 | 2011-03-31 | Novartis Ag | Formulations of deacetylase inhibitors |
US8519002B2 (en) | 2008-04-07 | 2013-08-27 | Takeda Pharmaceuticals U.S.A., Inc. | Colchicine solid complex; methods of making; and methods of use thereof |
US8003700B2 (en) * | 2008-04-07 | 2011-08-23 | Mutual Pharamaceutical Company, Inc. | Colchicine solid complex; methods of making; and methods of use thereof |
UY32297A (es) * | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
JP5263211B2 (ja) | 2010-03-30 | 2013-08-14 | ブラザー工業株式会社 | サーバ、プリンタ、及び、サーバのためのコンピュータプログラム |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
MA41544A (fr) | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
WO2017221163A1 (en) * | 2016-06-21 | 2017-12-28 | Alembic Pharmaceuticals Limited | Novel salts and polymorphic forms of panobinostat |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
JP2007501775A (ja) * | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
US20050228300A1 (en) * | 2004-04-07 | 2005-10-13 | Triage Data Networks | Cuffless blood-pressure monitor and accompanying wireless mobile device |
MY149337A (en) * | 2006-06-12 | 2013-08-30 | Novartis Ag | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
MY147013A (en) * | 2006-06-12 | 2012-10-15 | Novartis Ag | Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
-
2007
- 2007-06-07 JP JP2009515572A patent/JP2009540005A/ja active Pending
- 2007-06-07 RS RS20160199A patent/RS54640B1/en unknown
- 2007-06-07 US US12/302,571 patent/US20090197936A1/en not_active Abandoned
- 2007-06-07 EP EP07784348.0A patent/EP2032531B1/en active Active
- 2007-06-07 EA EA200802382A patent/EA015212B1/ru not_active IP Right Cessation
- 2007-06-07 ES ES07784348T patent/ES2570934T3/es active Active
- 2007-06-07 BR BRPI0712771-5A patent/BRPI0712771A2/pt not_active Application Discontinuation
- 2007-06-07 ME MEP-2008-879A patent/ME00531B/me unknown
- 2007-06-07 PL PL07784348T patent/PL2032531T3/pl unknown
- 2007-06-07 HU HUE07784348A patent/HUE027126T2/en unknown
- 2007-06-07 CA CA2654439A patent/CA2654439C/en active Active
- 2007-06-07 SM SM200900002T patent/SMP200900002B/it unknown
- 2007-06-07 KR KR1020157005106A patent/KR101629352B1/ko active Protection Beyond IP Right Term
- 2007-06-07 AU AU2007257962A patent/AU2007257962B2/en not_active Ceased
- 2007-06-07 NZ NZ572547A patent/NZ572547A/en not_active IP Right Cessation
- 2007-06-07 MX MX2008015901A patent/MX2008015901A/es not_active Application Discontinuation
- 2007-06-07 KR KR1020087030228A patent/KR20090026281A/ko not_active Application Discontinuation
- 2007-06-07 WO PCT/US2007/070558 patent/WO2007146715A1/en active Application Filing
- 2007-06-07 SI SI200731762A patent/SI2032531T1/sl unknown
- 2007-06-07 DK DK07784348.0T patent/DK2032531T3/en active
- 2007-06-07 GE GEAP200711010A patent/GEP20105125B/en unknown
- 2007-06-08 PE PE2007000725A patent/PE20080937A1/es active IP Right Grant
- 2007-06-08 TW TW096120759A patent/TWI409254B/zh not_active IP Right Cessation
- 2007-06-08 AR ARP070102500A patent/AR061298A1/es not_active Application Discontinuation
- 2007-06-11 UY UY30403A patent/UY30403A1/es not_active Application Discontinuation
- 2007-06-11 CL CL200701692A patent/CL2007001692A1/es unknown
- 2007-06-21 JO JOP/2007/0222A patent/JO3138B1/ar active
-
2008
- 2008-11-03 IL IL195087A patent/IL195087A/en unknown
- 2008-11-13 CR CR10439A patent/CR10439A/es unknown
- 2008-11-28 MY MYPI20084866A patent/MY147345A/en unknown
- 2008-12-02 TN TNP2008000501A patent/TNSN08501A1/en unknown
- 2008-12-10 GT GT200800279A patent/GT200800279A/es unknown
- 2008-12-11 HN HN2008001859A patent/HN2008001859A/es unknown
- 2008-12-12 SV SV2008003126A patent/SV2008003126A/es active IP Right Grant
- 2008-12-12 EC EC2008008979A patent/ECSP088979A/es unknown
- 2008-12-12 MA MA31469A patent/MA30563B1/fr unknown
-
2009
- 2009-01-09 NO NO20090128A patent/NO341871B1/no not_active IP Right Cessation
- 2009-06-17 HK HK09105414.8A patent/HK1126496A1/zh not_active IP Right Cessation
-
2010
- 2010-05-06 US US12/775,001 patent/US20100286409A1/en not_active Abandoned
-
2011
- 2011-01-14 US US13/006,485 patent/US20110112308A1/en not_active Abandoned
-
2013
- 2013-10-03 JP JP2013208363A patent/JP5771257B2/ja active Active
-
2016
- 2016-03-21 HR HRP20160291TT patent/HRP20160291T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007001692A1 (es) | Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina. | |
CY2017038I2 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων | |
CL2007001689A1 (es) | Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de prot | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
EA200901583A1 (ru) | N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды | |
CY2015016I2 (el) | Αναστολεις της κινασης τυροσινης του bruton | |
BRPI0720637A2 (pt) | Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto | |
BRPI0815009A2 (pt) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il) benzofuran-2-carboxamida, novas formas de sal, e métodos de uso do mesmo. | |
CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
BRPI0717757A2 (pt) | Derivado de haloalquilsulfoanilida ou um sal do mesmo, herbicida, e, método para usar um herbicida | |
BRPI0917540A2 (pt) | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável | |
TWI366460B (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
CL2007001451A1 (es) | Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas. | |
PA8750301A1 (es) | 4-[ 4{ 4-cloro-3-(trifluorometil)fenil] carbamoil}amino)-3-fluorofenoxi] -n-metilpiridin-2-carboxamida monohidratada | |
NO20092535L (no) | Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol | |
EA201070598A1 (ru) | Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
CL2007003158A1 (es) | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. | |
CL2007003645A1 (es) | Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria. | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" |